COVID-19 and IBD drugs: should we change anything at the moment?

Lees, Charlie W; Irving, Peter M; Beaugerie, Laurent

Lees, Charlie W; Irving, Peter M; Beaugerie, Laurent.

Lees CW; Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK charlie.lees@ed.ac.uk.
Irving PM; Centre for Genomics and Experimental Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK.
Beaugerie L; Department of Gastroenterology, Guy's and St Thomas' Hospital, London, UK.

Gut ; 70(4): 632-634, 2021 04.

Article in English | MEDLINE | ID: covidwho-936923

Subject(s)

COVID-19; Inflammatory Bowel Diseases; Pharmaceutical Preparations; Azathioprine; Humans; Inflammatory Bowel Diseases/drug therapy; Infliximab; Registries; SARS-CoV-2

Keywords

azathioprine; covid-19; crohn's disease; inflammatory bowel disease; infliximab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / Inflammatory Bowel Diseases / COVID-19 Limits: Humans Language: English Journal: Gut Year: 2021 Document Type: Article Affiliation country: Gutjnl-2020-323247

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google